Under a contract with Novartis, Harvard Pilgrim will receive a discount from the drug company if its Ernesto treatment for congestive heart failure does not result in a specified drop in patient hospitalizations, according to the article.
Under the other contract, Harvard Pilgrim has agreed to accept a lower rebate from Eli Lilly if its diabetes drug lowers patients’ hemoglobin levels better than drug competitors.
Novartis has already struck outcomes-based contracts for Ernesto with Cigna and Aetna.
More articles on payer issues:
UnitedHealth limits number of in-network insulin pumps, worries consumers
Florida Healthy Kids to end one insurance plan
N.D. insurance commissioner fines Sanford Health Plan over ads
At the Becker's 5th Annual Fall Payer Issues Roundtable, taking place November 2–3 in Chicago, payer executives and healthcare leaders will come together to discuss value-based care, regulatory changes, cost management strategies and innovations shaping the future of payer-provider collaboration. Apply for complimentary registration now.
